A detailed history of Corton Capital Inc. transactions in Arvinas, Inc. stock. As of the latest transaction made, Corton Capital Inc. holds 11,691 shares of ARVN stock, worth $291,339. This represents 0.15% of its overall portfolio holdings.

Number of Shares
11,691
Holding current value
$291,339
% of portfolio
0.15%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.66 - $32.73 $276,609 - $382,646
11,691 New
11,691 $287,000
Q1 2024

May 15, 2024

SELL
$36.38 - $52.31 $446,164 - $641,529
-12,264 Reduced 45.09%
14,935 $616,000
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $77,321 - $230,656
5,449 Added 25.05%
27,199 $1.12 Million
Q3 2023

Nov 14, 2023

BUY
$19.64 - $28.21 $243,752 - $350,114
12,411 Added 132.89%
21,750 $427,000
Q2 2023

Aug 14, 2023

BUY
$21.73 - $31.43 $202,936 - $293,524
9,339 New
9,339 $231,000
Q4 2022

Feb 14, 2023

BUY
$32.47 - $57.24 $38,249 - $67,428
1,178 Added 24.96%
5,898 $201,000
Q3 2022

Nov 14, 2022

BUY
$41.87 - $57.99 $197,626 - $273,712
4,720 New
4,720 $210,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.33B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Corton Capital Inc. Portfolio

Follow Corton Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Corton Capital Inc. with notifications on news.